AnaptysBio earnings ahead: First results as royalty company

AnaptysBio announced its second-quarter earnings on Monday, marking its first results since transitioning into a royalty management company from its drug development operations. The San Diego-based firm anticipates delivering a loss of $0.13 per share on $20.2 million in revenue for the quarter ending June 30. This marks a significant improvement in profitability, as losses narrowed from $1.84 per share in the first quarter, albeit with a revenue decline of approximately 21% from the prior quarter's $25.6 million.

The company now oversees financial collaborations for Jemperli with GlaxoSmithKline and imsidolimab with Vanda Pharmaceuticals, operating with a lean structure that emphasizes operational discipline and minimal full-time employees. Revenue primarily stems from tiered royalties on Jemperli, a PD-1 cancer drug, where AnaptysBio earns between 8% to 25% on global sales, contingent upon volume thresholds.

Analysts have maintained a Strong Buy rating for AnaptysBio, with a consensus price target of $87.09, suggesting a potential upside of nearly 49% from Friday's closing price of $56.02. Over the past 60 days, revenue estimates have declined by 14.29%, while EPS estimates remain unchanged.

The revenue trajectory will be a crucial factor in determining the company's future success. First-quarter collaboration revenue reached $25.6 million, with Jemperli royalties increasing by 44% to $24.7 million. Investors will closely monitor whether the sequential revenue decline is attributed to normal quarterly fluctuations or signals a slowdown in Jemperli sales growth at GSK.

The introduction of imsidolimab, whose FDA decision date for generalized pustular psoriasis is set for December 12, 2026, adds a potential catalyst revenue stream.

The recent quarter presented challenges for AnaptysBio, with the company missing first-quarter earnings estimates by 92%, posting a loss of $1.84 per share compared to expectations of 96 cents. However, revenue exceeded forecasts. The company completed the separation of First Tracks Biotherapeutics in April, starting with approximately $140 million to $145 million in net cash.

Monday's earnings report will be a pivotal test for the firm's strategy of becoming a pure-play royalty manager, with the ultimate goal of delivering sustainable profitability as Jemperli sales approach GSK's target of over $2.7 billion, which could generate more than $390 million in annual royalties for AnaptysBio.